Enterome fortifies Takeda relationship with $50M upfront to co-develop Crohn's drug
Privately held French biotech Enterome SA has scored a cool $50 million upfront to co-develop its experimental early-stage Crohn’s disease drug with Takeda in its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
